StockData

Longeveron vs Neurogene

LGVN and NGNE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and NGNE compare

Neurogene is the larger company, worth 6.9 times as much as Longeveron ($462M against $67.3M).

Neurogene scores higher on the StockData Score (7 against 5 for Longeveron), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNNGNE
Size and price
Market cap$67.3M$462M
Share price$2.11$23.10
Change, 1 year−69.0%1.4%
Change, 5 years−99.9%−77.4%
Beta (5Y)1.442.01
Employees37131
StockData Score
Total score57 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S56.7×–
P/B6.5×2.1× (better)
FCF yield−30.5%−19.0% (better)
Growth
Revenue growth (TTM)−42.7%–
Revenue growth, 5Y average−26.6%–
Profitability
Gross margin69.8%–
Operating margin−1993%–
Net margin−1978%–
FCF margin−1730%–
Return on equity−204%−45.3% (better)
Return on invested capital−1412%–
Financial health
Debt / equity0.000.00
Interest coverage–−60673.0×
Current ratio2.6310.64 (better)
Altman Z-score−9.427.17 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.5%86.5%
Held by insiders43.8%15.9%
Insider net buying, 12 months–−$1.1M
Short interest, % of float0.88%33.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.